To expand on the news about GEROPHARM's release of Semavic®, the company has introduced Semavic® as a domestic analogue to Ozempic®, responding to the cessation of Ozempic® imports from Denmark to Russia.
This review provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP) which is carried out by specialists of the Federal State Budgetary Institution "The All-Russian State Center for Quality and Standardization of Veterinary Drugs and Feed" (FSBI "VGNKI").
The Ministry of Health of the Russian Federation has authorized a Russian originator drug for the treatment of unresectable or metastatic melanoma. The product was developed by BIOCAD, a biotechnology company; it is a fixed dose combination of two monoclonal antibodies, nurulimab and prolgolimab.
This review provides information on the inspection of manufacturers of veterinary medicines for compliance with the GMP Rules requirements which is carried out by specialists of the Federal State Budgetary Institution "The All-Russian State Center for Quality and Standardization of Veterinary Drugs and Feed" (FSBI "VGNKI").
In January–June 2023, Russian manufacturers produced 342.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 2.6% from the same period in 2022.